检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
机构地区:[1]东南大学基础医学院江苏省生物材料和器件重点实验室,江苏南京210009 [2]东南大学临床医学院江苏省分子影像与功能影像重点实验室,江苏南京210009
出 处:《东南大学学报(医学版)》2009年第5期361-365,共5页Journal of Southeast University(Medical Science Edition)
基 金:国家863计划资助项目(2007AA03Z356);国家自然科学基金资助项目(30770584)
摘 要:目的:通过制备As2O3/Mn0.5Zn0.5Fe2O4复合纳米粒来研究热化疗对乳腺癌的治疗效果。方法:采用改良的化学沉淀-浸渍法制备As2O3/Mn0.5Zn0.5Fe2O4复合纳米粒,通过透射电镜、扫描电镜、能谱仪、原子荧光光谱仪来表征;检测As2O3/Mn0.5Zn0.5Fe2O4复合纳米粒的释药水平及在交变磁场中的升温能力;通过MTT比色法和流式细胞仪检测化疗组、热疗组及热化疗组乳腺癌的治疗效果。结果:制备的复合纳米粒粒径为20~40 nm;复合纳米粒体外升温能达到肿瘤的有效治疗温度(41~46℃);释药缓慢,48 h释药为14.67%。结论:采用改良的化学沉淀-浸渍法可以成功制备As2O3/Mn0.5Zn0.5Fe2O4复合纳米粒,体外实验证明该复合纳米粒联合交变磁场热疗对乳腺癌细胞具有很强的生长抑制和凋亡诱导作用。Objective To study the nano-As2O3/Mn0.5Zn0.5Fe2O4 particles's anticancer effect on human breast cancer cells through chemotherapy in combination with thermotherapy in alternating magnetic fields. Methods The nano-As2O3/Mn0.5Zn0.5Fe2O4 particles were prepared by improved technique of chemical co-precipitation and impregnation, and they were characterized by TEM, SEM,EDS and atom fluorescence spectrometer. The heat effect and the release ratio of As2O3 were studied under alternating magnetic fields in vitro. The treatment effect of human breast cancer cells was detected by M3T assay and FCM. Results The nano-As2O3/Mn0.5Zn0.5Fe2O4 particles had an average diameter of 30 nm and stable release ratio of 14. 67% , and they had very distinct heat effect in alternating magnetic fields and could rise to a steady temperature for tumor hyperthermia (41-46 ℃ ). Conclusions The nano-As2O3/Mn0.5Zn0.5Fe2O4 particles can be successfully made by improved technique of chemical co-precipitation and impregnation, and the nano-As2O3/Mn0.5Zn0.5Fe2O4 particles combined with magnetic hyperthermia have a strong role of inducing cell apoptosis.
关 键 词:As2O3/Mn0.5Zn0.5Fe2O4 纳米 热化疗 乳腺癌
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:18.219.40.177